Загрузка...
Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice
The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life...
Сохранить в:
| Главный автор: | |
|---|---|
| Формат: | Artigo |
| Язык: | Russo |
| Опубликовано: |
ABV-press
2021-09-01
|
| Серии: | Opuholi Ženskoj Reproduktivnoj Sistemy |
| Предметы: | |
| Online-ссылка: | https://ojrs.abvpress.ru/ojrs/article/view/845 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|